A new study points out the risk of nonsteroidal anti-inflammatory drug (NSAID) use in patients who have had a myocardial infarction (MI) suggesting that even brief use increases the risk for death and recurrent MI.
The FDA has approved linagliptin for the treatment of type 2 diabetes in adults.
The FDA has approved two new drugs for the treatment of hepatitis C the first new drugs to be approved in years.
Niacin may not be effective in preventing cardiovascular disease.
A wide variety of resources have been developed over the last several years, primarily Internet-based, to assist the critical care provider in managing patients in the ICU.
The purpose of this prospective, observational study was to report on the feasibility and safety of limiting sedation throughout a patient's ICU stay.
In this issue: Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
